Practice Patterns and Outcomes of Novel Targeted Agents for the Treatment of ERBB2-Positive Metastatic Breast Cancer.

ABSTRACT:

Importance

Clinical trials have shown that the addition of pertuzumab to trastuzumab-based chemotherapy for first-line treatment of ERBB2-positive metastatic breast cancer is associated with considerable improvement in overall survival (OS). In the second-line setting, trastuzumab emtansine (T-DM1) improves OS compared with capecitabine/lapatinib in patients previously treated with trastuzumab-based chemotherapy. However, there are few data describing long-term real-world outcomes with these agents.

Objective

To describe practice patterns and outcomes associated with pertuzumab and T-DM1 in routine clinical practice.

Design, setting, and participants

This population-based retrospective cohort study used the Ontario Cancer Registry linked to electronic treatment databa

SUBMITTER: Ethier JL 

PROVIDER: S-EPMC8267844 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature